Amol Akhade: Pembrolizumab shows EFS Benefit in Perioperative Head Neck SCC

Amol Akhade shared about Pembrolizumab’s Benefit in Perioperative Head Neck SCC. Read his post on LinkedIn below:

“Pembrolizumab shows EFS Benefit in Perioperative Head Neck SCC.

Keynote 689

Press Release.

It will be interesting to see full data.

Remember Pembrolizumab did not show benefit with CTRT alone in head neck SCC.”

More posts featuring Amol Akhade.

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.